SMIP004: A compound with antidepressant-like activities in mouse models

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Depression is a prevalent mood disorder with limited treatment options.
• S-phase kinase-associated protein 2 (Skp2) is implicated in cellular processes relevant to neurological function.
• Targeting Skp2 presents a potential novel therapeutic strategy for depression.

Purpose of the Study:

• To evaluate the antidepressant-like properties of SMIP004, a Skp2 inhibitor.
• To assess the efficacy of SMIP004 in mouse models of depression, including stressed conditions.
• To determine optimal dosage and administration for SMIP004's antidepressant effects.

Main Methods:

• Utilized tail suspension test (TST), forced swim test (FST), and sucrose preference test (SPT) in C57BL6/J mice.
• Administered SMIP004 acutely and chronically, with and without chronic unpredictable stress (CUS).
• Assessed locomotor activity using the open field test to confirm specificity of effects.

Main Results:

• SMIP004 exhibited antidepressant-like activity in naïve mice at 2 and 4 mg/kg, particularly with chronic or specific multi-dose acute administration.
• SMIP004 (2 mg/kg) reversed CUS-induced depressive behaviors and anhedonia.
• Combined SMIP004 and fluoxetine showed synergistic antidepressant effects; locomotor activity remained unaffected.

Conclusions:

• SMIP004 demonstrates significant antidepressant-like activities across multiple behavioral tests.
• SMIP004 effectively ameliorates depressive symptoms in stressed mouse models.
• SMIP004 represents a promising novel therapeutic candidate for depression treatment.